Recent Advances in Next-Generation Sequencing in Diagnostic Pathology

Dr. Sumana Pawar
Assistant Professor, MD, Pathology, YIMS, Yadagiri, Karnataka, India
Email: sumanapawar@gmail.com

Abstract
Next-generation sequencing (NGS) has revolutionized diagnostic pathology by offering more extensive and rapid genomic examination compared to traditional approaches. This review assesses the recent developments in NGS and their use in the diagnosis of diseases. The results based on secondary data illustrate advances in sequencing accuracy, long-read sequencing technologies, and clinical uses in the fields of oncology, hematology, genetic diseases, and infectious diseases. Nevertheless, NGS continues to be at the core of precision medicine despite issues associated with cost and implementation. The developments of the future based on artificial intelligence and the combination of multi-omics could help improve the practice of diagnosis and the outcomes of patients further.

{**Keywords:** ***Next-generation sequencing, diagnostic pathology, precision medicine, genomics, molecular diagnostics***]
How to cite this article: Pawar S. Recent Advances in Next-Generation Sequencing in Diagnostic Pathology. Int J Drug Deliv Technol. 2026;16(66s):1805-1810. DOI: 10.25258/ijddt.16.66s.196

1. Introduction

1.1 Background of the Study

Molecular pathology has grown to include an analysis of individual genetic markers up to the analysis of genomic data in large volumes. Conventional approaches, including Sanger sequencing, were better at enhancing disease diagnosis but were usually not as fast and large-scale as the complexity of diseases required. The rising pressure on data to be provided by accurate genomic diagnostics has led to an even higher demand on technologies capable of discovering numerous genetic alterations at the same time [7]. Next-generation sequencing (NGS) became a significant development as it has increased throughput, increased genomic coverage, and achieved a higher level of diagnostic accuracy. According to recent studies, NGS in the supplementation of personalized medicine is becoming more significant in contemporary diagnostic pathology practice across the globe through the provision of extensive molecular profiling [13].

1.2 Research Problem

Even though traditional diagnostic methods are highly useful, they tend to examine a small number of genetic targets and might not be sensitive to detecting more complex changes. This may postpone appropriate diagnosis and minimize chances of individualized treatment. Recent findings have shown that a range of genomic alterations that necessitate further analysis affect diseases like cancer. Although NGS can tackle most of these limitations by offering a method of high-throughput sequencing, issues of cost, interpreting data, and its application persist [1]. Thus, the assessment of recent progress and its practical significance to diagnostic pathology is gaining more and more significance.

1.3 Research Aim

The aim is to critically examine the recent developments in next-generation sequencing and determine the influence it has had on diagnostic pathology and clinical practice.

1.4 Research Objectives

- To analyze current technological advancements of next-generation sequencing.
- To compare the uses of diagnostics in pathology.
- To determine significant challenges and limitations.
- To investigate future health and clinical future opportunities.

1.5 Research Questions

1. What are the latest developments that have enhanced NGS technologies?
2. What is the use of NGS in diagnostic pathology?
3. What are the obstacles to more extensive use & implementation?
4. What are some of the future changes that will improve diagnosis efficacy?

1.6 Scope of the Review

This review will use a secondary research method as it will undertake a synthesis and analysis of published academic sources as evidence. Mainly, the discussion considers the studies published in 2021-2026 to guarantee the contemporary relevance. The enablement's of NGS in pathology in terms of technological progress, diagnostic uses, clinical

utility, and implementation issues are given particular attention. The study offers a review of the new evidence on the role of NGS in diagnostic practice by examining recent evidence to give a new insight into the role of NGS.

1.7 Structure of the Paper

The article includes a literature review, methodology, findings, discussion, and a conclusion. All of these sections discuss the recent advances in NGS and analyses its use in diagnosis, and speculate on the future impacts of NGS on diagnostic pathology, based on supporting evidence found in the current academic literature.

2. Literature Review



Figure 1: General Workflow of Next-Generation Sequencing (NGS)
(Source: 13)

2.1 Overview of Next-Generation Sequencing in Diagnostic Pathology

The next-generation sequencing (NGS) is a new technology that has revolutionized the diagnostic pathology and now allows multiple genetic alterations to be analyzed from a single clinical specimen. Conventional molecular diagnostic approaches generally emphasized genes, and were time consuming with less efficacy in complex diseases with prominent genomic signatures. Contrasted to this, NGS offers thorough molecule information, enabling pathologists to spot mutations, gene fusions, copy number variations, and additional genomic irregularities that are significant for diagnosis, prognosis, and benchmark how to select and tailor therapy.In comparison, NGS supplies comprehensive molecular information, empowering pathologists to identify mutations, gene fusions, copy number variations and more, that is relevant for diagnosis, prognosis, and treatment selection (Mandlik, Patil and Singh, 2024). In particular, the incorporation of NGS in oncology has had a profound impact in pathology. As per [5], NGS is valuable for precision medicine because it allows for the identification of specific markers in the tumour that can be utilized to direct targeted therapy and enhance outcomes. The technology also provides improved value to the diagnosis of cytology specimens. With the recent developments in molecular pathology, NGS has the power of providing reliable genomic information from small cytological samples without the need for an invasive tissue biopsy [4]. NGS has also found its uses in infectious disease pathology, in addition to cancer diagnostics. As long as sequencing technologies are available to identify pathogens and those conferring antimicrobial resistance in short order, then sequencing will enhance the management of complex infections as has been shown by [6]. Additionally, ongoing advancements in sequencing platforms, efficiency in workflows, and bioinformatics have contributed to the greater access and applicability of NGS ([13]; [9]). Therefore, NGS is now an integral part of a clinical diagnostic pathology and in combination of molecular and morphological information used to provide accurate clinical decisions.

2.2 Recent Technological Advances in NGS

Technology	Main Strength	Main Limitation
WGS	Entire genome analysis	High cost
WES	Focus on coding regions	Misses non-coding variants
Targeted Panels	Fast and cost-effective	Limited genomic coverage
Long-Read Sequencing	Detects structural variants	Higher infrastructure needs
Single-Cell Sequencing	Cell-level analysis	Complex data analysis

Table 1: Comparison of Major NGS Technologies
(Source: Self-created)

The use of next-generation sequencing (NGS) in diagnostic pathology has excelled in recent years in terms of performance and clinical application. The most significant advances are the parallel, high throughput, accurate and faster sequencer platforms available in the market today. [13] point out that the next generation sequencing (NGS) technologies now generate large amounts of high-quality genomic data with decreased costs, and thus they can be adopted in everyday clinical practice. Targeted panels of sequencing genes are also becoming a major development. These panels are different from the large, genomic assays, as they target clinically relevant genes involved in particular diseases, especially cancers. This way analysis becomes easy and can give immediate and actionable diagnostics information. [5] emphasize the significance of targeted NGS, as it has

played a pivotal role in the advancement of precision oncology by facilitating the discovery of predictive biomarkers for tailored therapeutic interventions. Another leap of innovation is the application of NGS to samples such as fine-needle aspiration and other minimal-cell-isolation samples, which are optimized for extraction and sequencing workflow, says [4]. This is a particular advantage to patients who are unable to have repeat surgical biopsy.

In addition, technological advances have increased the contribution of NGS in the diagnosis of infectious diseases. By using advanced sequencing methods, warn pathogens in a speedy manner, detect mixed infection, characterize antimicrobial resistance genes and enable rapid clinical intervention in a timely manner [6]. Concurrently, advancements in bioinformatics have reacted to the ability to interpret variants via automated pipelines, aid adaptation and growth of genomic databases through the assistance of artificial intelligence [9]. However, published research recognizes the ongoing problems of data interpretation, standardization of data reporting and the need for particular expertise. According to Mandlik, Patil, and Singh (2024), if it is to be a success, its implementation needs to ensure a strong quality control process and analytical frameworks validated. Taking this overall, recent technological advancements have contributed to the capacity of NGS and increased the importance of the method as a critical tool of modern diagnostic pathology.

2.3 Applications of NGS in Diagnostic Pathology

Recent articles show that NGS has revolutionized diagnostic pathology in various fields of disease. According to [5], NGS enhances cancer diagnostics by conducting a thorough tumors analysis, which allows for individual treatment decisions. Likewise, [2] notes its usefulness in hematological malignancies that are classified by genomic data rather than just by conventional morphology. In rare genetic diseases, as [1] add, targeted sequencing panels have been found to enhance the yield of diagnosis through the more effective identification of disease-inducing variants. In diagnostics of infectious diseases, [8] and [15] demonstrate that NGS makes it possible to detect pathogens very quickly, in situations when other diagnostic methods fail to provide clear results. In addition, liquid biopsy techniques offer a minimally invasive monitoring based on circulating tumour DNA analysis to foster benefits in disease surveillance compared with tissue biopsy. Nonetheless, there has been evidence to indicate that diagnostic benefits are different in various clinical settings. Although NGS provides bigger genomic information in comparison to conventional technologies, an effective implementation requires data quality, relevance of interpretation, and clinical knowledge, which implies that technological progress does not necessarily lead to better patient outcomes.

2.4 Research Gap

Recent studies are always well-documented with great improvements in the accuracy of sequencing, diagnostic capability, and clinical application of NGS. Nevertheless, there are still significant gaps. The current research is predominantly based on technological performance, but a smaller number of works are dedicated to a critical analysis of routine clinical integration. The consistency of standardization in different labs is still not totally stable and poses a problem with the comparability of results. Moreover, high implementation cost and complicated bioinformatics needs are also a restriction to accessibility. Despite the evidence that demonstrates the diagnostic utility of NGS, additional studies are necessary to overcome feasible limitations and encourage broader application in healthcare systems.

3. Methodology

3.1 Research Design

The research design utilized in this study was a qualitative literature-based design developed on a secondary research analysis [14]. Secondary research was appropriate as it can enable the gathering of prior research on the recent progress of the next-generation sequencing (NGS) without having to collect primary data.

3.2 Data Sources

The PubMed, Scopus, Web of Science, and Google Scholar were used to identify the relevant studies. These databases were chosen since they cover a wide range of peer-reviewed biomedical and pathology studies.

3.3 Inclusion Criteria & Exclusion Criteria

Inclusion: Peer-reviewed journal articles, published in English, during the years 2020-26 were also included in the review. The studies needed to concentrate on either NGS technologies, diagnostic pathology applications, clinical outcomes, or implementation challenges.

Exclusion: Publications that were not peer-reviewed or contained the same information, conference abstracts that lacked a complete text, and those studies that did not relate to NGS or diagnostic pathology were excluded.

3.4 Data Analysis Approach

Thematic analysis was used to determine common patterns among studies. The resulting information was then analyzed in a comparative synthesis methodology, which allowed critical analysis of technological developments, clinical use, and barriers to use and identified areas of concord and discord within the current literature [3].

4. Findings



Figure 2: Evolution of Sequencing Technologies
(Source: 11)

4.1 Major Technological Advances Identified

The studies reviewed provide consistent evidence of significant advances in NGS technologies. According to [1], [10], and [7], the sequencing accuracy has been enhanced by the use of high-quality platforms and better-analyzed working flows as compared to the previous systems, which have led to fewer diagnostic errors. Additional studies by [13] show that shorter turnaround times have led to improved clinical utility because they result in more timely decisions. Moreover, several studies provide an improved ability to detect genetic variations such as rare mutations and structural changes that cannot be detected by traditional sequencing. The other groundbreaking technology has been the introduction of long-read sequencing methods. [10] and [1] indicate that these platforms give better identifications of complex genomic regions. Overall, the evidence indicates that there is a growing diagnostic reliability brought about by recent technological advances, but it is possible that performance can differ across clinical environments.

4.2 Clinical Applications Identified

Application Area	Diagnostic Benefit
Cancer Diagnostics	Tumour profiling
Hematological Malignancies	Mutation identification
Rare Genetic Disorders	Improved diagnostic yield
Infectious Diseases	Pathogen detection
Liquid Biopsy	Non-invasive monitoring

Table 2: Clinical Applications of NGS in Diagnostic Pathology
(Source: Self-created)

The results indicate that NGS has extensive clinical uses in diagnostic pathology. [5], [7], and [4] highlight its precision oncology, where precision treatment depends on comprehensive genomic profiling to assist targeted treatment and personalized treatment strategies. Within hematological diagnostics, [2] suggests that NGS enhances the effectiveness of classifying disease and estimating risk through the identification of clinically relevant mutations. The literature reviews-based studies on the impact of NGS on rare diseases show that NGS can enhance the level of diagnostic yield by revealing genetic variations that many traditional methods tend to overlook. Additionally, [8] and [15] show that NGS enhances the ability to detect infectious diseases due to the quick identification of a pathogen and genomic surveillance. Comparative analysis reveals that despite the existing variation in the applications in different disease areas, a common advantage is the possibility to produce ample molecular information. This enhances a more accurate diagnosis and informed clinical decision-making as compared to traditional diagnostic methods.

4.3 Key Challenges Identified

Although it has advantages, various issues persist to constrain its widest implementation. Several studies report that high implementation costs represent one of the central obstacles, especially where there is a resource shortage in the healthcare environment ([1]; [7]). The complexity of bioinformatics is also high since large volumes of data need specific infrastructure and experience ([13]; [1]). Moreover, variants may be challenging to interpret in the case of clinical significance that is hard to recognize ([4];[2]). Encouraging ethical issues, including privacy of data, consent, and findings that happen during implementation, make implementation further complicated ([1]; [7]). Thus, it is indicated that solely technological advances cannot be achieved without tackling practical, clinical, and regulatory issues ([13]; [1]; [7]).

5. Discussion

Figure 3: Future Trends in Diagnostic Pathology
(Source: Self-created)

5.1 Interpretation of Findings

The results show that recent developments in NGS have been used to enhance the diagnostic potentials than older methods of sequencing. Research projects

conducted by ([13], [1] and [10]) posit that recent studies reveal that limitations identified in previous studies have been mitigated with sequencing accuracy, variant detection, and long-read technologies. Newer NGS platforms have a wider reach in terms of genomic data and are more diagnostic-specific than traditional formats. These developments facilitate the emerging theoretical trend of precision medicine, whereby the genome of an individual is becoming more and more central to their treatment decisions.

5.2 Impact on Diagnostic Pathology

The NGS has been shown to enhance diagnostic accuracy in all three publications, that is, [5], [2], and [4]), which refer to the fields of oncology, hematology, and testing for genetic diseases. The large-scale examination of genomes allows detecting disease earlier, and the identification of mutations that can be listed in clinical action plans is beneficial when developing personalised treatment regimens. In comparison to the more traditional methods of diagnosis, NGS produces richer molecular data, which can be used to make informed clinical decisions and enhance the patient management plan.

5.3 Critical Evaluation

Along with these advantages, there are significant drawbacks. NGS offers an extensive amount of genomic data and reinforcement of projects aimed at precision medicine; its usage is limited by infrastructure demands, data handling issues, and regulatory matters. According to [1] and [7], the achievement of successful clinical integration cannot be guaranteed solely through technological advancement. Thus, the organizational preparedness and professional knowledge prove to be crucial to optimizing diagnostic benefit.

5.4 Future Implications

The direction of AI-assisted genomic interpretation, multi-omics integration, and broader clinical adoption of AI should be expected in the future. Recent research indicates that these advancements can enhance the effectiveness of diagnosis and help to provide more personalized care [12]. But these benefits will only be realized with the help of standardization, training of the workforce and sustainable investment in healthcare systems.

According to recent works by [7], [1], and [13], the future of diagnostic pathology will be defined by artificial intelligence, multi-omics, and real-time sequencing. The innovations could enhance the interpretation of data, the speed of diagnosis, and clinical decisions compared to existing workflows. However, standardization, infrastructure, and expertise in the workforce are crucial to their success. The emphasis is that the combination of these technologies may help transform pathology into an activity that is more influenced by reactivity in diagnosis and make it more predictive, personalized, as well as data-driven models in healthcare across the globe.

6. Conclusion

This review observed that the latest innovations in NGS have made a tremendous impact on the accuracy of a diagnosis, variant localization, and the development of individual treatment plans. The aims of the research were attained through the consideration of technological advances, clinical practices, issues, and contemporary trends. Overall, NGS proved to be a significant instrument in contemporary diagnostic pathology and has several benefits over traditional practices. Nonetheless, further clinical practice implementation needs technical and operational obstacles to be overcome. High-tech applications in the future are expected to enhance the practice of precision medicine and pathology.

Reference List

[1] Brancato, D., Treccarichi, S., Bruno, F., Coniglio, E., Vinci, M., Saccone, S., Calì, F. and Federico, C., 2025. NGS approaches in clinical diagnostics: From workflow to disease-specific applications. *International Journal of Molecular Sciences*, *26*(19), p.9597.

[2] Cho, Y.U., 2024. The role of next-generation sequencing in hematologic malignancies. *Blood research*, *59*(1), p.11.

[3] Coker, D.C., 2022. A Thematic Analysis of the Structure of Delimitations in the Dissertation. *Online Submission*, *17*, pp.141-159.

[4] da Silva, R.S. and Schmitt, F., 2024. Next step of molecular pathology: next-generation sequencing in cytology. Journal of Pathology and Translational Medicine, 58(6), pp.291-298.

[5] Ghoreyshi, N., Heidari, R., Farhadi, A. *et al.* Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions. *Discov Onc* **16**, 578 (2025). https://doi.org/10.1007/s12672-025-01816-9

[6] Hilt, E.E. and Ferrieri, P., 2022. Next generation and other sequencing technologies in diagnostic microbiology and infectious diseases. *Genes*, *13*(9), p.1566.

[7] Isaic, A., Motofelea, N., Hoinoiu, T., Motofelea, A.C., Leancu, I.C., Stan, E., Gheorghe, S.R., Dutu, A.G. and Crintea, A., 2025. Next-generation sequencing: A review of its transformative impact on cancer diagnosis, treatment, and resistance management. *Diagnostics*, *15*(19), p.2425.

[8] Jabłońska, A., Sadkowski, A., Richert-Przygońska, M. and Styczyński, J., 2025. Next-generation sequencing for infectious disease diagnostics in pediatric patients with Malignancies or after hematopoietic cell

transplantation: A systematic review. *Journal of Clinical Medicine*, *14*(18), p.6444.

[9] Kumar, K.R., Cowley, M.J. and Davis, R.L., 2024, October. Next-generation sequencing and emerging technologies. In *Seminars in thrombosis and hemostasis* (Vol. 50, No. 07, pp. 1026-1038). Thieme Medical Publishers. Mandlik, J.S., Patil, A.S. and Singh, S., 2024. Next-generation sequencing (NGS): platforms and applications. *Journal of Pharmacy & Bioallied Sciences*, *16*(Suppl 1), p.S41.

[10] Kwon, R. and Yeung, C.C., 2024. Advances in next-generation sequencing and emerging technologies for hematologic malignancies. *Haematologica*, *109*(2), p.379.

[11] Lu, Y., Li, M., Gao, Z., Ma, H., Chong, Y., Hong, J., Wu, J., Wu, D., Xi, D. and Deng, W., 2025. Advances in whole genome sequencing: methods, tools, and applications in population genomics. International Journal of Molecular Sciences, 26(1), p.372.

[12] Parwani, A.V., 2019. Next generation diagnostic pathology: use of digital pathology and artificial intelligence tools to augment a pathological diagnosis. *Diagnostic pathology*, *14*(1), p.138.

[13] Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., Thakare, R.P., Banday, S., Mishra, A.K., Das, G. and Malonia, S.K., 2023. Next-Generation Sequencing Technology: Current Trends and Advancements. *Biology*, *12*(7), pp.997-997.

[14] Wickham, R.J., 2019. Secondary analysis research. *Journal of the advanced practitioner in oncology*, *10*(4), p.395.

[15] Xu, J.H., Cui, Y.B., Wang, L.J., Nan, H.J., Yang, P.Y., Bai, Y.L. and Shi, M.Y., 2024. Pathogen detection by targeted next-generation sequencing test in adult hematological malignancies patients with suspected infections. *Frontiers in medicine*, *11*, p.1443596.